Allergic Rhinitis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Allergic Rhinitis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Rhinitis Market.

The Allergic Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Allergic Rhinitis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Allergic Rhinitis treatment therapies with a considerable amount of success over the years.

*
Allergic Rhinitis companies working in the treatment market are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others, are developing therapies for the Allergic Rhinitis treatment

*
Emerging Allergic Rhinitis therapies in the different phases of clinical trials are- EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, Norketotifen, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others are expected to have a significant impact on the Allergic Rhinitis market in the coming years.

*
In March 2025, The National Allergy Centre of Excellence (NACE), based at Murdoch Children's Research Institute (MCRI), partnered with 17 Australian general practices and allergy clinics to introduce the ARISE trial for adolescents and young adults with hay fever. This study focuses on individuals aged 14 to 29 who experience hay fever, also known as allergic rhinitis.

*
In June 2024, Neurent Medical, a company at the forefront of developing non-surgical treatments for chronic inflammatory sinonasal conditions, today announced the publication of positive 12-month outcomes from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology. The study shows that treatment using Neurent Medical's NEUROMARK Registered radiofrequency (RF) ablation device is safe and leads to sustained, significant improvements in rhinitis symptoms and quality of life throughout the 12-month follow-up period.

Allergic Rhinitis Overview

Allergic rhinitis, commonly known as hay fever, is an inflammatory condition of the nasal passages caused by an allergic reaction to airborne allergens. These allergens can include pollen, mold spores, dust mites, animal dander, and certain air pollutants. When individuals with allergic rhinitis come into contact with these triggers, their immune system releases chemicals, such as histamines, leading to symptoms.

Get a Free Sample PDF Report to know more about Allergic Rhinitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight [https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Allergic Rhinitis Drugs Under Different Phases of Clinical Development Include:

*
FPP004: Funpep

*
INI 2004: Inimmune

*
TQC 3564: Chia Tai Tianqing Pharmaceutical Group

*
ILT-101: Iltoo Pharma

*
IRL201104: Revolo Biotherapeutics

*
PA9159: Anhui Palo Alto Pharmaceuticals

*
MM09-MG01: Immunotek SL

*
AI201901: Abdi Ibrahim Pharmaceuticals

*
REGN1908-1909: Regeneron

*
Glycopyranosyl lipid adjuvant: Revelation Biosciences

*
QX 005N: Qyuns Therapeutics

*
HY-083: Hyloris Pharmaceuticals

Allergic Rhinitis Route of Administration

Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Allergic Rhinitis Molecule Type

Allergic Rhinitis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Allergic Rhinitis Pipeline Therapeutics Assessment

*
Allergic Rhinitis Assessment by Product Type

*
Allergic Rhinitis By Stage and Product Type

*
Allergic Rhinitis Assessment by Route of Administration

*
Allergic Rhinitis By Stage and Route of Administration

*
Allergic Rhinitis Assessment by Molecule Type

*
Allergic Rhinitis by Stage and Molecule Type

DelveInsight's Allergic Rhinitis Report covers around 35+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Allergic Rhinitis product details are provided in the report. Download the Allergic Rhinitis pipeline report to learn more about the emerging Allergic Rhinitis therapies [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Allergic Rhinitis Therapeutics Market include:

Key companies developing therapies for Allergic Rhinitis are - Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, and others.

Allergic Rhinitis Pipeline Analysis:

The Allergic Rhinitis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.

*
Allergic Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Allergic Rhinitis drugs and therapies [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Allergic Rhinitis Pipeline Market Drivers

*
Increase in the prevalence of various form of allergic rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Allergic Rhinitis Market.

Allergic Rhinitis Pipeline Market Barriers

*
However, high competition from generic drugs, side-effects associated with the allergic rhinitis treatment and other factors are creating obstacles in the Allergic Rhinitis Market growth.

Scope of Allergic Rhinitis Pipeline Drug Insight

*
Coverage: Global

*
Key Allergic Rhinitis Companies: Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others

*
Key Allergic Rhinitis Therapies: EGN1908-1909, IRL201104, PA9159, AI201901, REGN 5713 5714 5715, CSPCHA115, MM09, CEN501, MG 01/T 517, Grass MATA MPL, REVTx-99b, ILT-101, AD17002, B244, DW2008, INI-2004, Norketotifen, STMC-103H, BM41, HY-083, QX 005N, FPP004, and others

*
Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies

*
Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers

Request for Sample PDF Report for Allergic Rhinitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/allergic-rhinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Allergic Rhinitis Report Introduction

2. Allergic Rhinitis Executive Summary

3. Allergic Rhinitis Overview

4. Allergic Rhinitis- Analytical Perspective In-depth Commercial Assessment

5. Allergic Rhinitis Pipeline Therapeutics

6. Allergic Rhinitis Late Stage Products (Phase II/III)

7. Allergic Rhinitis Mid Stage Products (Phase II)

8. Allergic Rhinitis Early Stage Products (Phase I)

9. Allergic Rhinitis Preclinical Stage Products

10. Allergic Rhinitis Therapeutics Assessment

11. Allergic Rhinitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Allergic Rhinitis Key Companies

14. Allergic Rhinitis Key Products

15. Allergic Rhinitis Unmet Needs

16 . Allergic Rhinitis Market Drivers and Barriers

17. Allergic Rhinitis Future Perspectives and Conclusion

18. Allergic Rhinitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-rhinitis-pipeline-2025-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-inmunotek-iltoo-pharma-advagene-biopharma-co-ltd-aobiome-llc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.